UB Paderborn / Katalog / Suche / in CDI

Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P‐glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar

International journal of cancer, 2014-03, Vol.134 (6), p.1484-1494

2014

Volltextzugriff (PDF)

Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2)

Pharmacological research, 2015-12, Vol.102, p.200-207

2015

Volltextzugriff (PDF)

Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1)

Pharmaceutical research, 2015-07, Vol.32 (7), p.2205-2216

2015

Volltextzugriff (PDF)

Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation

Pharmacological research, 2017-06, Vol.120, p.43-50

2017

Volltextzugriff (PDF)

Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699)

Pharmaceutical research, 2015-01, Vol.32 (1), p.37-46

2015

Volltextzugriff (PDF)

Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein)

Pharmacological research, 2019-08, Vol.146, p.104297, Article 104297

2019

Volltextzugriff (PDF)

Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2008-09, Vol.872 (1), p.1-22

2008

Volltextzugriff (PDF)

Chromatographic bioanalytical assays for targeted covalent kinase inhibitors and their metabolites

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2021-01, Vol.1162, p.122466-122466, Article 122466

2021

Volltextzugriff (PDF)

OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation

British journal of pharmacology, 2020-07, Vol.177 (13), p.3060-3074

2020

Volltextzugriff (PDF)

Collagen degradation and neutrophilic infiltration: a vicious circle in inflammatory bowel disease

Gut, 2014-04, Vol.63 (4), p.578-587

2014

Volltextzugriff (PDF)

ABCB1 attenuates brain exposure to the KRASG12C inhibitor opnurasib whereas binding to mouse carboxylesterase 1c influences its plasma exposure

Biomedicine & pharmacotherapy, 2024-06, Vol.175, p.116720, Article 116720

2024

Volltextzugriff (PDF)

P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability

Pharmacological research, 2018-11, Vol.137, p.47-55

2018

Volltextzugriff (PDF)

Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells

Pharmaceutical research, 2018-04, Vol.35 (4), p.85-15, Article 85

2018

Volltextzugriff (PDF)

The ABCB1 and ABCG2 efflux transporters limit brain disposition of the SYK inhibitors entospletinib and lanraplenib

Toxicology and applied pharmacology, 2024-04, Vol.485, p.116911-116911, Article 116911

2024

Volltextzugriff (PDF)

P‐glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450‐3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib

International journal of cancer, 2018-10, Vol.143 (8), p.2029-2038

2018

Volltextzugriff (PDF)

Liquid chromatography–tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2016-09, Vol.1031, p.80-85

2016

Volltextzugriff (PDF)

ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib

Pharmacological research, 2021-10, Vol.172, p.105850, Article 105850

2021

Volltextzugriff (PDF)

Bioanalytical liquid chromatography-tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates

Journal of pharmaceutical and biomedical analysis, 2018-11, Vol.161, p.136-143

2018

Volltextzugriff (PDF)

Development and validation of an LC-MS/MS method for the quantification of KRASG12C inhibitor opnurasib in several mouse matrices and its application in a pharmacokinetic mouse study

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2024-01, Vol.1232, p.123964-123964, Article 123964

2024

Volltextzugriff (PDF)

Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation

Molecular cancer therapeutics, 2010-02, Vol.9 (2), p.319-326

2010

Volltextzugriff (PDF)

Pharmacokinetics of the KRASG12C inhibitor adagrasib is limited by CYP3A and ABCB1, and influenced by binding to mouse plasma carboxylesterase 1c

Biomedicine & pharmacotherapy, 2023-10, Vol.166, p.115304-115304, Article 115304

2023

Volltextzugriff (PDF)

Organic anion-transporting polypeptide 2B1 knockout and humanized mice; insights into the handling of bilirubin and drugs

Pharmacological research, 2023-04, Vol.190, p.106724-106724, Article 106724

2023

Volltextzugriff (PDF)

Quantitative bioanalytical assay for the selective RET inhibitors selpercatinib and pralsetinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2020-06, Vol.1147, p.122131, Article 122131

2020

Volltextzugriff (PDF)

Bioanalytical assay for the novel TRK inhibitor selitrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2019-08, Vol.1122-1123, p.78-82

2019

Volltextzugriff (PDF)

Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib

European journal of pharmaceutics and biopharmaceutics, 2019-03, Vol.136, p.120-130

2019

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P‐glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar

Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2)

Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1)

Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation

Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699)

Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein)

Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry

Chromatographic bioanalytical assays for targeted covalent kinase inhibitors and their metabolites

OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation

Collagen degradation and neutrophilic infiltration: a vicious circle in inflammatory bowel disease

ABCB1 attenuates brain exposure to the KRASG12C inhibitor opnurasib whereas binding to mouse carboxylesterase 1c influences its plasma exposure

P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability

Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells

The ABCB1 and ABCG2 efflux transporters limit brain disposition of the SYK inhibitors entospletinib and lanraplenib

P‐glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450‐3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib

Liquid chromatography–tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma

ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib

Bioanalytical liquid chromatography-tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates

Development and validation of an LC-MS/MS method for the quantification of KRASG12C inhibitor opnurasib in several mouse matrices and its application in a pharmacokinetic mouse study

Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation

Pharmacokinetics of the KRASG12C inhibitor adagrasib is limited by CYP3A and ABCB1, and influenced by binding to mouse plasma carboxylesterase 1c

Organic anion-transporting polypeptide 2B1 knockout and humanized mice; insights into the handling of bilirubin and drugs

Quantitative bioanalytical assay for the selective RET inhibitors selpercatinib and pralsetinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry

Bioanalytical assay for the novel TRK inhibitor selitrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry

Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib

Suchergebnisse filtern